Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Gross Margin (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Gross Margin for 6 consecutive years, with 90.07% as the latest value for Q1 2018.

  • On a quarterly basis, Gross Margin rose 837.0% to 90.07% in Q1 2018 year-over-year; TTM through Mar 2018 was 69.49%, a 86054.0% decrease, with the full-year FY2017 number at 60.81%, down 1990.0% from a year prior.
  • Gross Margin was 90.07% for Q1 2018 at Theravance Biopharma, up from 30.99% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 113.77% in Q4 2015 to a low of 124.84% in Q4 2014.
  • A 5-year average of 74.52% and a median of 90.62% in 2014 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -22484bps in 2014, then soared 23862bps in 2015.
  • Theravance Biopharma's Gross Margin stood at 124.84% in 2014, then surged by 191bps to 113.77% in 2015, then decreased by -9bps to 104.1% in 2016, then tumbled by -70bps to 30.99% in 2017, then skyrocketed by 191bps to 90.07% in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Gross Margin are 90.07% (Q1 2018), 30.99% (Q4 2017), and 76.96% (Q3 2017).